A quick sniff of a nasal spray sends microscopic metal particles into the brain, where they target and destroy the damaging proteins of Alzheimer’s disease.
No Alzheimer’s? No problem—the metal particles pass out of the body safely. Such is the promise of technology being developed by neuroscientist William Klein and nanotechnologist Vinayak Dravid of Northwestern University. The pair has invented a nanotech-based early-detection system that might one day deliver targeted treatments.
Klein and Dravid created an antibody—an immune molecule that detects specific chemical structures—that binds to a particle implicated in Alzheimer’s. They linked the antibody to a nanoscale arrangement of iron oxide compounds, similar to rust, which can be seen with magnetic resonance imaging. The brain scan could detect the disease early on, so patients can start treatment sooner than they can today. “Once the chain reaction of negative events starts, it’s like a lit fuse. You want to intervene as soon as possible,” Klein says.
Globs of beta-amyloid protein called plaques are a hallmark of Alzheimer’s. But these days most neuroscientists agree that a tiny particle form of the same protein, called an oligomer, is the primary toxin in the illness. Eventually these smaller structures glom together to form plaques, but by then they have already damaged brain cells. The antibody created at Northwestern binds to the toxic oligomers and could one day deliver therapies to the brain or help clinicians evaluate how a patient is responding to a new medication.
The Latest on: Alzheimer’s Disease
- WKU students biking cross-country to raise funds for Alzheimer’s researchon July 6, 2019 at 9:01 pm
The students bike an average of 70 miles a day, stopping in various cities to spread awareness of the impact Alzheimer’s disease has. “They say one in six are affected by Alzheimer’s or know someone ... […]
- Colorado Alzheimer’s researchers shift focus after failures; begin testing leukemia medicine as treatmenton July 6, 2019 at 8:23 pm
It just dumped them on revenue reports under “other.” But now researchers in Colorado are testing Leukine’s ability to regulate the immune system as a treatment for Alzheimer’s disease. The possible ... […]
- Dementia tied to hormone-blocking prostate cancer treatmenton July 5, 2019 at 11:39 am
Alzheimer's disease may be a risk for older prostate cancer patients given hormone-blocking treatment, a large, U.S. government-funded analysis found. Previous evidence has been mixed on whether ... […]
- Caring for someone with dementia, Alzheimer's disease? USU offering free online courseon July 4, 2019 at 6:48 am
SALT LAKE CITY — Few caregivers are trained to care for loved ones who have Alzheimer's disease or other forms of dementia, which can make them feel isolated and underprepared, says Utah State ... […]
- New Markers For Alzheimer's Disease Could Aid Diagnosis And Speed Up Drug Developmenton July 4, 2019 at 4:20 am
Alzheimer's disease begins altering the brain long before it affects memory and thinking. So scientists are developing a range of tests to detect these changes in the brain, which include an increase ... […]
- INmune Bio Co-Founder and CEO Presents at Maxim Group’s Conference on Alzheimer’s Diseaseon July 3, 2019 at 7:01 am
INmune Bio Co-Founder and CEO Presents at Maxim Group's Conference on Alzheimer's Disease LA JOLLA, Calif., July 03, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), an immunology company ... […]
- Q&A: Searching for infectious cause of Alzheimer’s diseaseon July 2, 2019 at 10:00 am
The Infectious Diseases Society of America Foundation announced that it will award five one-time grants of $100,000 to researchers investigating a potential infectious cause of Alzheimer’s disease. ... […]
- Alzheimer's Is Not Just an "Old People's" Diseaseon July 1, 2019 at 12:43 pm
In April of 2018, my 62 year old sister was diagnosed with younger-onset Alzheimer's disease. Sadly, my family is very familiar with Alzheimer's. Between 2000 when my father was diagnosed with the ... […]
- Blood Test for Alzheimer's Disease Oneon June 28, 2019 at 11:04 am
An accurate, fully automated blood test for Alzheimer's disease (AD) that can be used in primary care settings may be one step closer, results of a large prospective study suggest. Using a ... […]
- Biohaven, Anavex, And Neurotrope: Addressing The Role Of Protein Kinase C In Alzheimer's Diseaseon June 28, 2019 at 8:00 am
Protein kinase C over-activation plays a critical role in the onset and early progression of Alzheimer's disease. Biohaven's prodrugs directly inhibit protein kinase C. Anavex 2-73 indirectly ... […]
via Google News and Bing News